Earnings Feed
Start Free
ZEVRA THERAPEUTICS, INC.·4

Feb 2, 5:19 PM ET

Quartel Adrian W 4

Research Summary

AI-generated summary

Updated

Zevra Therapeutics (ZVRA) CMO Adrian W. Quartel Sells Shares

What Happened

  • Adrian W. Quartel, Chief Medical Officer of Zevra Therapeutics (ZVRA), reported several equity transactions around Jan 29–30, 2026. The headline item: he sold 4,533 shares in an open‑market transaction at a weighted average price of $8.83 for total proceeds of $40,036.
  • The filing also shows equity awards and derivative activity: grants of 37,500 restricted stock units (RSUs) and 75,000 stock options on Jan 29, 2026, and the vesting/settlement/exercise of 11,333 derivative shares on Jan 30 (one‑third of an award settled per footnote).

Key Details

  • Transaction dates: grants recorded 2026-01-29; vest/settlement and sale executed 2026-01-30.
  • Sale price: weighted average $8.83 (individual trades ranged $8.62–$9.04). Proceeds reported: $40,036. (Reporting person offered to provide breakdown of individual trade prices/quantities on request per the filing.)
  • Grants: 37,500 RSUs (F1/F4/F6) and 75,000 stock option grant (F5). Per footnotes, one‑third of the RSUs vested and settled on Jan 30, 2026; remaining RSUs vest in equal annual installments thereafter subject to continued service. The option vests in four equal annual installments beginning one year after grant.
  • 10b5‑1 plan: filing notes a 10b5‑1 trading plan adoption date of 3/26/2025 (F2), indicating the sale may have been executed under a pre‑arranged plan.
  • Shares owned after the transactions: not specified in this Form 4 filing.
  • Timeliness: Form filed 2026-02-02 for transactions on Jan 29–30, 2026; the filing does not indicate a late filing.

Context

  • This filing combines routine equity compensation activity (RSU grants, an option grant, vesting/settlement) with a small open‑market sale. Sales executed under a 10b5‑1 plan are typically pre‑arranged and routine; the sale here was modest (~$40k) relative to the size of the grants.
  • For derivative items: the filing lists exercises/settlements of derivative awards (treated as conversions/vestings), and some of the shares that vested/settled were sold in the open market. The filing is factual; it does not state motivations.